Sunday 18 October 2026
Export ENGN’s income statement to Excel — free account
enGene Therapeutics Inc
ENGN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 18.2%, free cash flow grew 28.1% and total debt rose 42.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.67
0.04
−2.34%
Follow ENGN
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.28%) | (46.07%) | (52.58%) | (60.50%) | |
| (44.05%) | (39.30%) | (44.19%) | (48.84%) | ||
ROIC |
0.00% | (263.83%) | (384.73%) | 0.00% | |
Return on Tangible Assets |
(68.24%) | (45.85%) | (50.57%) | (51.56%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.97) | (1.54) | (1.60) | (1.49) | |
Free Cash Flow |
(100.72) | (103.78) | (111.39) | (104.00) | |
Capital Expenditures |
(1.48) | (1.34) | (1.39) | (0.69) | |
| Other line items | |||||
Cash ROIC |
(26.73%) | (17.82%) | (20.68%) | (19.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(41.14) | (42.95) | (44.42) | (44.51) | |
Operating CF/Net income |
0.85 | 0.84 | 0.87 | 0.79 | |
Depreciation/Fixed assets |
(1.03) | (0.93) | (0.64) | (0.50) | |
Capex/Depreciation |
0.58 | 0.59 | 0.92 | 0.64 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.94) | (1.52) | (1.58) | (1.48) | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026